Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

6/25/2015 Hemispherx Receives the European Patent Office Examining Division’s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen® Formulations

6/4/2015 Hemispherx Biopharma Announces Preliminary Approval of Securities Class Action Settlement

5/26/2015 Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen /Rintatolimod for Ebola Virus Disease (EVD)

5/20/2015 Hemispherx to Present at the Marcum Microcap Conference in New York
….Planned Launch of Alferon N Injection® Highlighted


5/13/2015 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2015
…..Newly Upgraded Alferon Facility Completed; Production of New Alferon API Inventory Commenced in February 2015; Our European Subsidiary Received Formal Notification of Approval of Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients with Ebola Virus Disease (EVD)


More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com